Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

D. Wiviott, Stephen; Raz, Itamar; P. Bonaca, Marc; Mosenzon, Ofri; Kato, Eri; Cahn, Avivit; G. Silverman, Michael; A. Zelniker, Thomas; Kuder, Julia; A. Murphy, Sabina; L. Bhatt, Deepak; A. Leiter, Lawrence; K. McGuire, Darren; Wilding, John; T. Ruff, Christian; Gause‐Nilsson, Ingrid; Fredriksson, Martin; A. Johansson, Peter; Langkilde, Anna-Maria; S. Sabatine, Marc

doi:10.1056/nejmoa1812389

Public

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Published in New England Journal of Medicine • Nov 10, 2018

Authors:

Stephen D. Wiviott

Itamar Raz

Marc P. Bonaca

Abstract

BACKGROUND: The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined. METHODS: of body-surface area, new end-stage renal disease, or death from renal or cardiovascular causes) a...

Subject

Dapagliflozin

Mace

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!